awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33754114-4CE8D62B-49D8-464A-92D5-AC1DA7F7752B
Q33754114-4CE8D62B-49D8-464A-92D5-AC1DA7F7752B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33754114-4CE8D62B-49D8-464A-92D5-AC1DA7F7752B
The new concepts on overcoming drug resistance in lung cancer.
P2860
Q33754114-4CE8D62B-49D8-464A-92D5-AC1DA7F7752B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33754114-4CE8D62B-49D8-464A-92D5-AC1DA7F7752B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
72458e6173ce1822107492c03b71f984ba22400f
P2860
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.